Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Barclays Remains a Buy on Boston Scientific (BSX)

AI-generated analysis

πŸ“ˆ Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00.

πŸ’° The company reported quarterly revenue of $5.2 billion and net profit of $1.34 billion for the quarter ending March 31.

πŸ“Š Revenue grew from $4.66 billion last year, while net profit increased significantly from $674 million to $1.34 billion.

πŸ‘₯ Corporate insider sentiment is positive with 61 insiders showing increased buying activity over the past quarter.

🏦 Director Edward Ludwig recently purchased 3,580 shares for a total value of $202,914.40 earlier this month.

πŸ“‰ TD Cowen reiterated a Buy rating on the stock but set a lower price target of $80.00 compared to Barclays.

🩺 Analyst Robbie Marcus cited intact long-term growth outlook despite near-term headwinds related to WATCHMAN products.

πŸ₯ Miksic covers the Healthcare sector including peers like Johnson & Johnson and Becton Dickinson.

πŸ“Š TipRanks data indicates Miksic has a 49.48% success rate on recommended stocks with an average return of 1.5%.

⚠️ The article notes various other analyst actions including Stifel lowering the price target to $75 from $85.

Bullish Signals
  • Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00.
  • TD Cowen also reiterated a Buy rating on the stock with a $80.00 price target.
  • The company reported quarterly revenue of $5.2 billion and net profit of $1.34 billion, representing significant growth from last year's $4.66 billion revenue and $674 million net profit.
  • Corporate insider sentiment is positive with an increase in insider buying over the past quarter, highlighted by Director Edward Ludwig purchasing 3,580 shares for $202,914.40.
  • Analysts cite an intact long-term growth outlook and TAVR expansion as key drivers supporting the stock despite near-term headwinds.
Risk Factors
  • Boston Scientific's WatchMAN device faces near-term headwinds that could impact short-term revenue growth despite long-term optimism.
  • Analyst Stifel lowered Boston Scientific's price target from $85 to $75, indicating a reduction in valuation expectations.
  • The article mentions the stock is 'crashing today', suggesting significant recent volatility or negative market sentiment.
Full Analysis
Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00, citing strong fundamentals despite recent market volatility. The recommendation follows a similar stance from TD Cowen, which reiterated a Buy rating with an $80.00 price target based on the company's latest earnings for the quarter ending March 31. Boston Scientific reported quarterly revenue of $5.2 billion and net profit of $1.34 billion, representing significant growth compared to last year's figures of $4.66 billion in revenue and $674 million in net profit. Corporate insider sentiment remains positive, with data from TipRanks indicating increased buying activity among 61 insiders over the past quarter. Notably, Edward Ludwig, a Director at BSX, purchased 3,580 shares for approximately $202,914 earlier this month. While Miksic covers the broader Healthcare sector including peers like Johnson & Johnson and Becton Dickinson, his specific focus on Boston Scientific highlights its long-term growth potential even as it navigates near-term headwinds related to the WATCHMAN product line.